Summary of Galectin Therapeutics (GALT) Update / Briefing Company Overview - **Company**: Galectin Therapeutics (GALT) - **Focus**: Development of belapectin as a treatment for NASH cirrhosis and portal hypertension, addressing a significant unmet medical need [2][4] Industry Context - **Condition**: NASH cirrhosis is a leading cause of liver transplantation in the US, with an estimated 5 million adults affected, including 3.3 million with portal hypertension [8][9] - **Market Opportunity**: Belapectin is positioned as a first-in-class therapy for NASH cirrhosis, with peak sales potential estimated at $18 billion [15] Clinical Trial Insights - **Clinical Trials**: Multiple Phase IIb trials conducted, including the NAVIGATE trial, which focused on patients with NASH cirrhosis and portal hypertension [5][19] - **Mechanism of Action**: Belapectin is a Galectin-3 inhibitor, which has shown anti-inflammatory and anti-fibrotic effects in preclinical studies [5][6] NAVIGATE Trial Findings - **Patient Population**: Included patients with compensated NASH cirrhosis and portal hypertension, with no baseline varices [20][21] - **Primary Endpoint**: Focused on the development of esophageal varices and other hepatic decompensation events [22][36] - **Results**: - Statistically significant reduction in new varices in the belapectin 2 mg/kg group (11.3% vs. 22.3% in placebo) [27] - Reduction in liver stiffness observed, indicating less disease progression [28][30] - Safety profile comparable to placebo, with no significant adverse events reported [31][37] Key Opinion Leaders' Perspectives - **Expert Opinions**: KOLs emphasized the urgent need for effective therapies in the NASH cirrhosis population, highlighting belapectin's potential to fill this gap [8][9][12] - **Market Feedback**: Positive responses from payers and physicians regarding the clinical and economic benefits of belapectin [14] Additional Insights - **Endoscopic Endpoint**: The NAVIGATE trial utilized centrally adjudicated endoscopy videos to track variceal development, enhancing the reliability of results [39][41] - **Comparison with Other Therapies**: Belapectin targets a more advanced patient population compared to other investigational therapies, which often select for less severe cases [62][63] Conclusion - **Future Outlook**: Belapectin shows promise in addressing the unmet needs of patients with advanced NASH cirrhosis and portal hypertension, with a favorable safety profile and significant market potential [36][60]

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Compass Diversified’s (NYSE: CODI) tumultuous spring continued as Jefferies analysts recently downgraded the company’s stock amid a sweeping securities class action lawsuit filed by investors, both moves stemming from a widening accounting scandal at its Lugano subsidiary.  The dual blows—Wall Street’s loss of confidence and mounting legal challenges—have sent Compass’s shares into a tailspin, erasing over 70% of the company’s market value over the past three ...

本文摘自：2025年6月13日发布的 TS合约的持仓集中度如何解读 唐元懋 ，资格证书编号： S0880524040002 我们认为造成这一现象的核心是低利率环境、债市谨慎情绪与高 IRR 的共同作用。 首先， TS 合约 IRR 策略性价比较高， TS2506 合约切换至主力合约时 IRR 已经达到 2.3% ，并且后续也持续在 2% 以上， 至 4 月上旬一度达到 2.7% ， TS 合约正套策略性价比较高；其次，市场情绪相对谨慎，对中性策略接 受度更高；最后，低利率环境下正套策略提供的收益率相较以往具有更为突出的吸引力。 TS 空单集中至个别会员机构上的现象在 2024 年年初至 2024 年 5 月也曾经发生过，复盘来看， 2024 年 TS 合约空单集中到分散可以分为以下三个阶段。① 2024 年初至 2024 年 5 月：正套资金入场带动 TS 空单集中至单个会员机构。 2023 年末债市"抢跑"行为驱动下多头情绪迅速升温， TS 合约基差下降 至 -0.24 元， IRR 则最高攀升至 3.4% ，吸引正套资金入场带动 TS 空单集中至单个会员机构， ②单个 机构 TS 合约空单持仓占比触顶回落 ...

金融研究 2025年6月13日 星期五 金融期货早班车 招商期货有限公司 市场表现：6 月 12 日，A 股四大股指涨跌不一，其中上证指数上涨 0.01%，报收 3402.66 点；深成 指下跌 0.11%，报收 10234.33 点；创业板指上涨 0.26%，报收 2067.15 点；科创 50 指数下跌 0.3%， 报收 977.97 点。市场成交 13,036 亿元，较前日增加 169 亿元。行业板块方面，有色金属(+1.4%)， 传媒(+1.33%)，美容护理(+1.31%)涨幅居前；家用电器(-1.77%)，煤炭(-1.14%)，食品饮料(-1.13%) 跌幅居前。从市场强弱看，IC>IM>IH>IF，个股涨/平/跌数分别为 2,325/224/2,864。沪深两市，机构、 主力、大户、散户全天资金分别净流入-5、-87、-18、111 亿元，分别变动 0、-43、+34、+9 亿元。 基差：IM、IC、IF、IH 次月合约基差分别为 132.42、99.53、50.6 与 45.28 点，基差年化收益率分 别为-19.8%、-15.89%、-12.04%与-15.58%，三年期历史分位数分别为 4 ...

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine reminds investors who purchased stock in Compass Group Diversified Holdings, LLC (NYSE: CODI) between May 1, 2024, and May 7, 2025 have less than one month to seek appointment as lead plaintiff in a pending action against Compass.  Compass is an investment holding company and one of its subsidiary businesses is Lugano Holdings, Inc., a jewelry company. WHAT’S THIS ABOUT?On March 7, 2025, Compass announced that an ongoing ...

NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertens ...

金融研究 2025年6月10日 星期二 金融期货早班车 招商期货有限公司 市场表现：6 月 9 日，A 股四大股指全线上涨，其中上证指数上涨 0.43%，报收 3399.77 点；深成指 上涨 0.65%，报收 10250.14 点；创业板指上涨 1.07%，报收 2061.29 点；科创 50 指数上涨 0.6%， 报收 997.61 点。市场成交 13,127 亿元，较前日增加 1,354 亿元。行业板块方面，医药生物(+2.3%)， 农林牧渔(+1.72%)，纺织服饰(+1.61%)涨幅居前；食品饮料(-0.43%)，汽车(+0.03%)，家用电器 (+0.04%)跌幅居前。从市场强弱看，IM>IC>IF>IH，个股涨/平/跌数分别为 4,120/200/1,092。沪深两 市，机构、主力、大户、散户全天资金分别净流入 57、-59、-73、76 亿元，分别变动+133、+59、 -86、-107 亿元。 股指期货 基差：IM、IC、IF、IH 次月合约基差分别为 142.36、109.65、53.05 与 40.83 点，基差年化收益率 分别为-19.08%、-15.74%、-11.38%与-12.6 ...

NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Management L.P. (“Prospect”), investment adviser to Prospect Capital Corporation (NASDAQ: PSEC) and other funds, announced today that Prospect Capital Corporation’s President and Chief Operating Officer, Grier Eliasek, is featured in the June 2025 Private Debt Investor (“PDI”) Middle Market Direct Lending Report. In the Q&A-format feature, Mr. Eliasek highlights the attractive opportunities in the lower and core middle-market, where lenders have t ...

Core Viewpoint - Shares of Compass Diversified (NYSE: CODI) fell nearly 15% in intraday trading due to troubling accounting practices at a subsidiary, leading to a securities class action lawsuit [1] Financial Measures - Compass Diversified announced urgent liquidity measures including a forbearance agreement with lenders, reduction in management fees, and suspension of quarterly cash distributions [2] - The company will also curtail new investments in Lugano Holdings, the subsidiary involved in the controversy, to focus on its other eight portfolio companies [2] Regulatory Issues - The New York Stock Exchange notified Compass that it is out of compliance with listing requirements due to delayed quarterly report filings, facing a six-month deadline to remedy the situation or risk delisting [3] Legal Actions - A securities class action lawsuit was filed in California, alleging that Compass and executives misled investors about the financial health of Lugano Holdings, claiming undisclosed financing arrangements and irregularities in financial statements [4][5] - The lawsuit contends that Compass's internal controls were inadequate and key information was withheld from shareholders [5] Financial Impact - On May 7, Compass revealed "irregularities" in Lugano's financial practices, leading to a sell-off that erased more than half of the company's market value in one day [6] - Following this, Compass announced a delay in releasing its first-quarter 2025 financial results as an internal investigation is ongoing [6] Investigative Actions - Hagens Berman is investigating potential securities violations by Compass Diversified, indicating the severity of the financial reporting issues [7]